Shinobi Therapeutics Inc.

• Developing allogeneic iPS cell therapies: Shinobi focuses on creating "off-the-shelf" cell therapies derived from induced pluripotent stem cells (iPSCs). These therapies are designed to be compatible with multiple patients, overcoming the limitations of current cell therapies that often require complex and time-consuming manufacturing processes.

• Immune Evasion Technology: Shinobi's core innovation lies in its ability to engineer iPSC-derived cells to evade the patient's immune system, minimizing the risk of rejection and enabling repeated dosing. Pipeline:

Shinobi's pipeline includes a promising portfolio of iPS cell-based therapies targeting:

• Solid tumors: Developing therapies for various solid cancers, including those with high unmet medical needs. Autoimmune diseases: Exploring the potential of iPS cell therapies to address challenging autoimmune conditions. Impact:

Shinobi's innovative approach has the potential to:

• Transform the treatment of cancer and other diseases: By overcoming the limitations of current cell therapies, Shinobi aims to provide more effective and accessible treatments for patients.

• Advance the field of regenerative medicine: Shinobi's research and development efforts contribute significantly to the advancement of iPSC technology and its clinical translation. Note:

This is a general overview. For the most accurate and up-to-date information about Shinobi Therapeutics Inc., please refer to their official website and other reliable sources.

Disclaimer: This information is for general knowledge and informational purposes only and should not be considered financial or investment advice.